Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension

Autor: Scott S. Billecke, Pamela A. Marcovitz
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Drug
medicine.medical_specialty
Time Factors
medicine.drug_class
calcium channel blocker
Endocrinology
Diabetes and Metabolism
media_common.quotation_subject
Blood Pressure
Calcium channel blocker
Review
Benzoates
Risk Factors
Diabetes mellitus
Internal medicine
Medicine
Humans
Pharmacology (medical)
Amlodipine
antihypertensive
Telmisartan
Angiotensin receptor blocker
Intensive care medicine
Antihypertensive Agents
media_common
biology
business.industry
Patient Selection
Public Health
Environmental and Occupational Health
Angiotensin-converting enzyme
clinical trial
Hematology
General Medicine
medicine.disease
Calcium Channel Blockers
Angiotensin II
Clinical trial
Drug Combinations
Endocrinology
Treatment Outcome
Hypertension
biology.protein
Benzimidazoles
Cardiology and Cardiovascular Medicine
business
Angiotensin II Type 1 Receptor Blockers
medicine.drug
combination pill
Zdroj: Vascular Health and Risk Management
ISSN: 1178-2048
1176-6344
Popis: The use of multiple drug regimens is increasingly recognized as a tacit requirement for the management of hypertension, a necessity fueled in part by rising rates of metabolic syndrome and diabetes. By targeting complementary pathways, combinations of antihypertensive drugs can be applied to provide effective blood pressure control while minimizing side effects and reducing exposure to high doses of individual medications. In addition, combination therapies, including angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs), have the added benefit of reducing cardiovascular mortality and morbidity over other dual therapies while providing equivalent blood pressure control. It is possible that angiotensin receptor blockers (ARBs), which unlike ACE inhibitors are minimally affected by upregulation of alternative pathways for angiotensin II accumulation following long-term treatment, would also provide such outcome benefits. At issue, however, is maintaining patient compliance, as adding medications is known to reduce adherence to treatment regimens. The purpose of this review is to summarize existing trial data for the long-term safety and efficacy of a recent addition to the armamentarium of dual-antihypertensive therapeutic options, the telmisartan/amlodipine single pill combination. The areas where long-term data are lacking, notably clinical information regarding minorities and women, will also be discussed.
Databáze: OpenAIRE
Externí odkaz: